Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BHV-7000 in bipolar I disorder
NCT06423794Phase 2Terminated
- Sponsor
- Biohaven Ltd.
- Start
- Jun 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of opakalim in bipolar I disorder, sponsored by Biohaven Ltd. Primary endpoints: Clinically Significant Laboratory Abnormalities at 52 weeks, Adverse Events at 52 weeks and 2 more. Started Jun 2024; status: terminated.
02
Drugs
opakalim
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT06423794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06423794.